Dr. Haeseong Park, MD
Claim this profileWashington University School of Medicine
Studies Solid Tumors
Studies Pancreatic Cancer
27 reported clinical trials
55 drugs studied
About Haeseong Park, MD
Education:
- MD from Washington University School of Medicine, 2018.
- Residency in Internal Medicine at Washington University School of Medicine, 2021.
- Fellowship in Cardiovascular Disease at Washington University School of Medicine, expected completion in 2024.
Experience:
- Comprehensive training and experience at Washington University School of Medicine in St. Louis, Missouri, specializing in Internal Medicine and Cardiovascular Disease.
Area of expertise
1Solid Tumors
Stage IV
Stage III
HER2
2Pancreatic Cancer
Stage IV
Stage III
HER2 positive
Affiliated Hospitals
Clinical Trials Haeseong Park, MD is currently running
Chemotherapy + Immunotherapy
for Esophageal and Gastric Cancer
This phase III trial compares the effect of modified fluorouracil, leucovorin calcium, oxaliplatin, and irinotecan (mFOLFIRINOX) to modified fluorouracil, leucovorin calcium, and oxaliplatin (mFOLFOX) for the treatment of advanced, unresectable, or metastatic HER2 negative esophageal, gastroesophageal junction, and gastric adenocarcinoma. The usual approach for patients is treatment with FOLFOX chemotherapy. Chemotherapy drugs work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Fluorouracil stops cells from making DNA and it may kill tumor cells. Leucovorin is used with fluorouracil to enhance the effects of the drug. Oxaliplatin works by killing, stopping, or slowing the growth of tumor cells. Some patients also receive an immunotherapy drug, nivolumab, in addition to FOLFOX chemotherapy. Immunotherapy may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Irinotecan blocks certain enzymes needed for cell division and DNA repair, and it may kill tumor cells. Adding irinotecan to the FOLFOX regimen could shrink the cancer and extend the life of patients with advanced gastroesophageal cancers.
Recruiting2 awards Phase 32 criteria
TAB004 + Toripalimab
for Solid Cancers
The primary objective is to assess the safety and tolerability of TAB004 as monotherapy and in combination with toripalimab in subjects with selected advanced solid malignancies, including lymphoma, and to evaluate the recommended Phase 2 dose. The secondary objectives are to: 1) describe the pharmacokinetic (PK) profile of TAB004 monotherapy and in combination with toripalimab and to describe the PK profile of toripalimab when administered with TAB004, 2) evaluate antitumor activity of TAB004 monotherapy and in combination with toripalimab; and 3) determine the immunogenicity of TAB004 monotherapy and in combination with toripalimab and to determine the immunogenicity of toripalimab when administered with TAB004. The exploratory objectives are to: 1) evaluate pharmacodynamic effects of TAB004 on its target receptor BTLA, as well as effects on the immune system; 2) evaluate biomarkers that may correlate with activity of TAB004 as monotherapy and in combination with toripalimab; 3) evaluate the utility of BTLA ligand, herpesvirus-entry mediator (HVEM), and additional exploratory biomarkers that could aid in selection of appropriate subjects for TAB004 monotherapy and in combination with toripalimab.
Recruiting1 award Phase 110 criteria
More about Haeseong Park, MD
Clinical Trial Related7 years of experience running clinical trials · Led 27 trials as a Principal Investigator · 8 Active Clinical TrialsTreatments Haeseong Park, MD has experience with
- Nivolumab
- Leucovorin
- Pembrolizumab
- Oxaliplatin
- Trastuzumab
- Capecitabine
Breakdown of trials Haeseong Park, MD has run
Solid Tumors
Pancreatic Cancer
Esophageal Cancer
Stomach Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Haeseong Park, MD specialize in?
Haeseong Park, MD focuses on Solid Tumors and Pancreatic Cancer. In particular, much of their work with Solid Tumors has involved Stage IV patients, or patients who are Stage III.
Is Haeseong Park, MD currently recruiting for clinical trials?
Yes, Haeseong Park, MD is currently recruiting for 8 clinical trials in Saint Louis Missouri. If you're interested in participating, you should apply.
Are there any treatments that Haeseong Park, MD has studied deeply?
Yes, Haeseong Park, MD has studied treatments such as Nivolumab, Leucovorin, Pembrolizumab.
What is the best way to schedule an appointment with Haeseong Park, MD?
Apply for one of the trials that Haeseong Park, MD is conducting.
What is the office address of Haeseong Park, MD?
The office of Haeseong Park, MD is located at: Washington University School of Medicine, Saint Louis, Missouri 63110 United States. This is the address for their practice at the Washington University School of Medicine.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.